Detalhe da pesquisa
1.
Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Nat Rev Cancer
; 7(6): 441-53, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17522713
2.
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Blood
; 122(4): 515-22, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704092
3.
Natural course and biology of CML.
Ann Hematol
; 94 Suppl 2: S107-21, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814077
4.
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Blood
; 118(13): 3634-44, 2011 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-21821701
5.
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Br J Haematol
; 157(4): 446-56, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22372463
6.
Wrapping BCR-ABL: it's in the bag.
Blood
; 116(18): 3382-3, 2010 Nov 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-21051563
7.
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Blood
; 116(8): 1329-35, 2010 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20462961
8.
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
Blood
; 115(2): 315-25, 2010 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-19837975
9.
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood
; 115(21): 4206-16, 2010 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20299508
10.
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Biochim Biophys Acta
; 1804(10): 1974-87, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20417730
11.
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Blood
; 114(27): 5426-35, 2009 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19880502
12.
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
Blood
; 112(5): 2163-6, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18565849
13.
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Clin Cancer Res
; 15(10): 3442-50, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19401345
14.
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia.
Nat Commun
; 10(1): 4741, 2019 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628323
15.
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
Int J Cancer
; 122(5): 1058-67, 2008 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17955490
16.
BCR-ABL in chronic myelogenous leukemia--how does it work?
Acta Haematol
; 119(4): 212-7, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18566539
17.
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.
Clin Cancer Res
; 13(17): 5048-55, 2007 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17785556
18.
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
Mol Cancer Ther
; 6(2): 655-66, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17267662
19.
Another Year to Celebrate Advances in Clinical Hematology.
Clin Hematol Int
; 5(1): 1-2, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36940020
20.
Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.
Neoplasia
; 20(6): 632-642, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29772458